Evaluation of Antiparkinson’s activity of Uncaria rhynchophylla, Mentha aquatica and Banisteriopsis caapi-plants with Monoamine Oxidase-B (MAO-B) inhibition potential

Abstract

The study revealed the anti-Parkinson’s activity of three herbal extracts (that Uncaria rhynchophylla, Mentha aquatica and Banisteriopsis caapi and its combination) in 6-OHDA induced Parkinson’s models. In the standard experimental conditions, all the three extracts showed significant anti-parkinson’s activity. The postural and neuro-humoral defects were normalised by the all test drugs. The systematic pharmacological analysis revealed that Uncaria rhynchophylla, Mentha aquatica and Banisteriopsis caapi- plants could be a anti-Parkinson’s remedy, and earlier these three plants were ethanopharmacologically proven for its anti oxidant, anti ulcer, antiseptic, antispasmodic, anti diabetic, immunostimulent, anti cancer and CNS activities. The evaluation of anti Parkinson’s activities of these plants might be leading to a new drug molecule or herbal moiety which can ameliorate the anti- Parkinson’s drug toxicities or can be an anti Parkinson’s drug in future. The extracts showed significant anti-Parkinson’s activity in 6-OHDA lesioned rat models, but the lead identification was not carried out in this study. The estimated parameters were closely relevant to clinical Parkinsonism and the drug treatment protected the diseased brain of rat. The time constrains to complete this research and nature of experiment made us to restrict experiments specific to pharmacology. Our invention on these herbal drugs shall be an information to further carryout the lead identification for preclinical pharmacology, and we propose suitable lead optimization from these extracts. And we appreciate further detailed molecular studies with these leads in anti-Parkinson’s pharmacology and toxicology. From these findings we suggest that, these drug molecules could be a future drug of choice for the treatment of clinical Parkinsonism